Loading...

Idorsia Ltd

IDRSFPNK
Healthcare
Biotechnology
$3.50
$0.00(0.00%)

Idorsia Ltd (IDRSF) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Idorsia Ltd (IDRSF), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-26.17%
26.17%
Operating Income Growth
9.07%
9.07%
Net Income Growth
11.47%
11.47%
Operating Cash Flow Growth
41.17%
41.17%
Operating Margin
-47.77%
47.77%
Gross Margin
82.79%
82.79%
Net Profit Margin
-61.36%
61.36%
ROE
11.56%
11.56%
ROIC
-67.16%
67.16%

Idorsia Ltd (IDRSF) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Idorsia Ltd IDRSF financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$58.88M$59.90M$22.70M$16.35M
Cost of Revenue$2.44M$52.60M$14.97M$5.06M
Gross Profit$56.44M$7.29M$7.74M$11.29M
Gross Profit Ratio$0.96$0.12$0.34$0.69
R&D Expenses$27.45M$32.71M$30.91M$34.37M
SG&A Expenses$52.40M$66.80M$55.94M$73.97M
Operating Expenses-$10.22M$85.55M$86.85M$108.34M
Total Costs & Expenses-$7.78M$138.16M$115.83M$113.40M
Interest Income$0.00$0.00-$6.17M$0.00
Interest Expense$7.54M$5.46M$5.07M$4.38M
Depreciation & Amortization$4.33M$4.20M$4.86M$4.22M
EBITDA$75.38M-$54.85M-$78.14M-$99.72M
EBITDA Ratio$1.28-$0.92-$3.44-$6.10
Operating Income$66.67M-$78.25M-$89.63M-$97.05M
Operating Income Ratio$1.13-$1.31-$3.95-$5.94
Other Income/Expenses (Net)-$3.15M-$5.89M-$11.24M-$11.27M
Income Before Tax$63.51M-$84.14M-$100.86M-$108.32M
Income Before Tax Ratio$1.08-$1.40-$4.44-$6.63
Income Tax Expense$393000.00-$136000.00$173000.00$251000.00
Net Income$63.12M-$84.005M-$101.00M-$108.57M
Net Income Ratio$1.07-$1.40-$4.45-$6.64
EPS$0.33-$0.45-$0.56-$0.60
Diluted EPS$0.23-$0.45-$0.55-$0.60
Weighted Avg Shares Outstanding$188.89M$188.21M$181.58M$179.90M
Weighted Avg Shares Outstanding (Diluted)$182.45M$188.30M$182.38M$179.90M

The company's financials show resilient growth, with revenue advancing from $16.35M in Q2 2024 to $58.88M in Q1 2025. Gross profit remained healthy with margins at 96% in Q1 2025 compared to 69% in Q2 2024. Operating income hit $66.67M last quarter, sustaining a consistent 113% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $75.38M. Net income rose to $63.12M, while earnings per share reached $0.33. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;